NEW YORK, July 18 - Bristol-Myers Squibb and Exelixis said Wednesday that they had signed a collaboration and licensing deal targeted at developing new cancer drugs.

Under the terms of the deal, Bristol-Myers Squibb of Princeton, NJ, will make an equity investment in Exelixis, which will use its knock-out technology to identify and validate targets that can trigger cell death in cancerous cells while leaving healthy cells unharmed. Bristol-Myers will then further analyze the targets in humans. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.